Apple (AAPL): Steve Jobs Is Fine

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Steve_jobsConcern about the health of Apple (AAPL) CEO and founder Steve Jobs has been mounting since his appearance to launch the iPhone 3G model. He was terribly thin. Earlier this week, the press raised the issue again and  when the company’s CFO said during the Apple earnings call that Jobs health was a "private matter," investors grew more restless.

Chris Whitmore, an analyst with Deutsche Bank, wrote that "while the topic is delicate, we believe the absence of a straightforward denial of health issues will increase speculation of a worst case scenario.", according to MarketWatch.

There are two sides to the disclosure issues about Jobs health and how SEC regulations could be interpreted, particularly because Apple is as close as a "one person" company as any large corporation in the world. There is a strong argument that the company does not have to disclose whether Jobs currently has cancer or not. He had successful treatment for pancreatic cancer in late 2003. If there has not been a previous denial that he is sick or any other misleading statement, Apple may not be obliged to say anything if Jobs has become ill again.

The other, more compelling argument, is that the Apple board is a collection of high-powered people whose reputations are important to them and their companies. Arthur Levinson, the CEO of Genentech (DNA) is on the board. So is Eric Schmidt of Google (GOOG), Andrea Jung of Avon (AVP), and Al Gore. The board has already faced uncomfortable issues about the privacy surrounding Jobs 2003 illness and later about stock options grant investigation which might have damaged the CEO’s ability to stay on as CEO.

With a group like this as the Apple board, it is extremely likely that they would do both the ethical thing, from the standpoint of shareholders, and the smartest and most conservative thing from a disclosure standpoint.

Apple has said nothing.  The board would not dodge the issue of Jobs health if he is ailing.

Jobs is fine, or, the Apple board has a problem.

Douglas A. McIntyre

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618